Atlas Venture — Full Portfolio

Intellia Therapeutics develops in vivo and ex vivo CRISPR/Cas9 gene editing therapies aimed at treating the root causes of severe genetic diseases, with lead candidates for hereditary angioedema and ATTR amyloidosis.

BiotechDeep TechHealthtechCambridge, US

Nessan Bermingham(Executive Officer, Director)Jennifer Doudna(Co-founder)Jose Rivera(Executive Officer)John Leonard(President and Chief Executive Officer)James Basta(Executive Vice President, General Counsel and Corporate Secretary)Edward Dulac(Executive Vice President, Chief Financial Officer)

Board seatJean-François Formela· per SEC Form D

Co-investorsage1Avoro Capital AdvisorsEcoR1 CapitalForesite Capital

BiotechArlington, US

Darius Kharabi(Executive Officer)Todd Bazemore(Executive Officer)Mark Iwicki(Executive Officer, Director)Mary Reumuth(Executive Officer)Kim Brazzell(Executive Officer)Charles McDermott(Executive Officer)

Board seatKevin Bitterman· per SEC Form D · $7M raise · filed Aug 2015

Co-investorsLongitude CapitalSR One Capital ManagementYsios CapitalLux CapitalThird Rock Ventures

Korro Bio is a biotechnology company developing a new class of RNA-editing therapies guided by human genetics and disease biology.

BiotechHealthtechCambridge, US

Nessan Bermingham(Mr. Bermingham is the Executive Chair of the Issuer.)Ommer Chohan(Mr. Chohan is the Secretary and Treasurer of the Issuer.)in

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D

Co-investorsMC Healthcare VenturesNew Enterprise Associates (NEA)

HealthtechMalvern, US

Mark R. Bausinger(Executive Officer)Christopher Thatcher(Executive Officer, Director)

BoardStephen Campe(Director)Robert Kuhling(Director)Liam Ratcliffe(Director)P. Sherrill Neff(Director)

Board seatKevin Bitterman· per SEC Form D · $34.3M raise · filed May 2015

Co-investors1315 CapitalAscension Ventures

Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for immune-mediated diseases, led by SP001, a third-generation anti-CD40L antibody targeting IgG4-related disease.

BiotechCambridge, US

Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)

BoardJean-Francois Formela(Director)inReza Halse(Director)Casper Breum(Director)Vikas Goyal(Director)

Board seatJean-François Formela· per SEC Form D · $40M raise · filed Jul 2021

Co-investorsHEALTHCARE ROYALTY PARTNERSMRL Ventures FundOUP (Osage University Partners)RA CapitalAlphabet

Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology therapies that use protein engineering to remain inactive until activated by tumor-specific proteases within the tumor microenvironment.

BiotechHealthtechWaltham, US

Rene Russo(Executive Officer, Director)inJoseph Farmer(Executive Officer)Timothy Clackson(Executive Officer)Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)

Board seatDavid Grayzel· per SEC Form D · $95M raise · filed Feb 2021

Co-investorsBain Capital Life SciencesBay City CapitalF-Prime CapitalM VenturesMRL Ventures FundRA Capital+4 more

Disc Medicine is a biopharmaceutical company developing therapies from discovery through clinical development for patients in need.

BiotechHealthtech

John Quisel(Chief Executive Officer)Jean Franchi(Chief Financial Officer)Jonathan Yu(Chief Operating Officer)Will Savage(Chief Medical Officer)Pamela Stephenson(Chief Commercial Officer)Steve Caffé(Chief Regulatory Officer)

Co-investorsAccess BiotechnologyBain Capital Life SciencesForesite CapitalFrazier Life SciencesOrbiMed

Dyne Therapeutics develops targeted therapies for genetically driven neuromuscular diseases using its proprietary FORCE platform.

BiotechMedical DevicesWaltham, US

Romesh Subramanian, Ph.D.(Executive Officer)Richard Scalzo(Executive Officer)Joshua Brumm(Executive Officer, Director)Jonathan McNeill, M.D.(Executive Officer)Oxana Beskrovnaya, Ph.D.(Executive Officer)

BoardLawrence Klein, Ph.D.(Director)

Co-investorsMPM BioImpactVida VenturesForbionHercules Capital, Inc.

Exelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types.

BiotechHealthtechSan Francisco Bay Area, US

Johnson & Johnson develops prescription medicines and medical technology across areas including oncology, immunology, neuroscience, cardiopulmonary, cardiovascular, orthopaedics, surgery, and vision.

BiotechHealthtechMedical DevicesNew Brunswick, US

Joaquin Duatoin

Co-investorsAisling CapitalNaviMed CapitalPortland Seed FundSPRINGROCK VENTURESThe Column GroupvenBio Partners

Kymera is a clinical-stage biotechnology company developing novel medicines using targeted protein degradation technology to treat diseases caused by previously "undrugged" proteins.

BiotechDeep TechHealthtech

Nello Mainolfi(Founder)in

Co-investorsAvoro Capital AdvisorsBain Capital Life SciencesBessemer Venture PartnersHatteras Venture PartnersMRL Ventures FundNextech Invest+3 more

Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to kill tumors locally and trigger a systemic anti-tumor immune response.

BiotechHealthtech

Synlogic develops synthetic biology-based biotherapeutics that use engineered living organisms to treat diseases.

BiotechDeep TechMedical DevicesCambridge, US

Bharatt Chowrira(Executive Officer)Michael Sheahan(Executive Officer)Jose Carlos Gutierrez-Ramos(Executive Officer, Director)Paul Miller(Executive Officer)Aoife Brennan(Executive Officer)Todd Shegog(Executive Officer)

Co-investorsNew Enterprise Associates (NEA)NSG VenturesPfizer Venture InvestmentsSofinnova VenturesSolasta VenturesOrbiMed

Cogent Biosciences is a biotechnology company developing small molecule precision therapies for genetically driven diseases where the cause is linked to a specific genetic mutation.

BiotechDigital HealthHealthtechLongevityMedical DevicesCambridge, US

Charles Wilson(Executive Officer, Director)Christiana Stamoulis(Executive Officer)

BoardBen Auspitz(Director)Liam Ratcliffe(Director)Bruce Booth(Director)in

Co-investorsF-Prime Capital

Antares Therapeutics discovers and develops precision medicines, with a focus on small molecule therapies targeting previously undruggable oncology targets and other serious diseases.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Adam Friedman(Chief Executive Officer)inAndrew Fedder(Executive Officer, Director)inBrian Piper(Executive Officer, Director)

Board seatJean-François Formela· per SEC Form D

Co-investorsLightspeed Venture PartnersVida VenturesOmega FundsTenmileAbingworthBiotechnology Value Fund

Comanche Biopharma is a biopharmaceutical company developing an investigational siRNA medicine (CBP-4888) targeting a root cause of preterm preeclampsia in pregnant women.

BiotechFemTechHealthtechConcord, US

Mike Young(Founder)T Scott Johnson(Founder)inPaul Antinori(Executive Officer)Allison August(Executive Officer)Michael Young(Executive Officer)Thomas Scott Johnson(Executive Officer, Director)

Board seatDavid Grayzel· per SEC Form D

Co-investorsGV (Google Ventures)Broadview VenturesF-Prime CapitalLilly Asia VenturesNew Enterprise Associates (NEA)

IFM Therapeutics develops small-molecule drugs that target the innate immune system to treat inflammation-driven diseases and cancer.

BiotechHealthtechCambridge, US

Gary Glick(Mr. Glick is a director and the President of the Issuer.)Gary D. Glick(Founder)H. Martin Seidel(Chief Executive Officer)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D

Co-investorsAbingworth

Kinaset Therapeutics is a drug developer working on KN-002, a therapeutic candidate for treating severe asthma across patients regardless of the underlying cause of inflammation.

BiotechHealthtechMedfield, US

Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher O’Brien(Chief Medical Officer)

BoardJamil Beg(Director of the Issuer)inTom King(Director of the Issuer)

Board seatKevin Bitterman· per SEC Form D

Co-investors5AM VenturesRA CapitalEQT Life SciencesSixty Degree CapitalVivo CapitalGimv+1 more

Remix Therapeutics develops RNA reprogramming technology to treat various diseases and disorders.

AI & Machine LearningBiotechWatertown, US

Peter Smith, PhD(Co-Founder, President and Chief Executive Officer)Peter Smith(Co-Founder, President and Chief Executive Officer)Robert Gagnon(Executive Officer)Heather Wasserman(Executive Officer)Matthew Patterson(Director)Scott Biller(Director)

Board seatKevin Bitterman· per SEC Form D

Co-investorsForesite CapitalThe Column GroupARCH Venture PartnersDecheng Capital

Caldera is a clinical-stage biotechnology company developing CLD-423, a bispecific antibody targeting the IL-23p19 and TL1A pathways for inflammatory bowel disease and other immunologic and inflammatory diseases.

BiotechHealthtech

Praveen Tipirneni(Chief Executive Officer)Liangsu Wang(Chief Scientific Officer)Zhong Liu(Chief Technology Officer)Aaron Pelta(Chief Business Officer)Colm White(Chief Program Officer)

Co-investorsJanus Henderson InvestorsLAVvenBio Partners

Ethyreal Bio is a biopharmaceutical company developing medicines for people with Thyroid Eye Disease and Graves' Disease.

BiotechHealthtechCambridge, US

Niranjan Kameswaran(Chief Executive Officer)Jessica Stromme(Chief Development Officer)Kelly Foster(Chief Scientific Officer)Stephen Huang(Senior Vice President, Head of Clinical Development)Simon Read(Chairman of the Board and Independent Board Member)

Co-investorsAvoro Capital AdvisorsMedicxi

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform.

BiotechHealthtechCambridge, US

Andrew Fraley(Co-founder)OMMER CHOHAN(Executive Officer)JAMES JEFFREY GOATER(Executive Officer, Director)CHELSEA PLACE JOHNSON(Director)Simon Read(CEO)Alfica Sehgal

Co-investorsDigitalis VenturesThe Column GroupDroia VenturesYK Bioventures

Lifordi Immunotherapeutics develops treatments for immunology and rare diseases through discovery, clinical development, and commercialization.

BiotechDeep TechHealthtech

Arthur O. Tzianabos, Ph.D.(President and CEO)Naina Bhasin, Ph.D.(Chief Business Officer)

Co-investorsARCH Venture PartnersSanofi Ventures5AM Ventures

nChroma Bio develops in vivo targeted delivery and genetic engineering technologies for genetic medicine applications.

BiotechDeep TechMedical Devices

Luke Gilbert, PhDKeith Joung, MD, PhDDavid Liu, PhDAngelo Lombardo, PhDLuigi Naldini, MD, PhDJonathan Weissman, PhD

Co-investorsNewpath PartnersARCH Venture PartnersDCVC (Data Collective)F-Prime Capital5AM VenturesDCVC Bio+1 more

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsBiotechnology Value FundForbionLightspeed Venture PartnersResearch Corporation TechnologiesTCG Crossover

Rectify Pharma is a biotechnology company developing therapies, with a pipeline that has included work in liver and metabolic disease areas.

BiotechDeep Tech

Rajesh Devraj(President and Chief Executive Officer)Robert Hughes(Chief Scientific Officer)Pol Boudes(Chief Medical Officer)

Co-investorsDC Investment PartnersLongwood Fund

Sionna Therapeutics is a biopharmaceutical company founded in 2019 that develops small-molecule therapies for cystic fibrosis by targeting and stabilizing NBD1, the domain of the CFTR protein where the common ΔF508 mutation occurs.

BiotechHealthtechMedical Devices

Greg(Co-founder & Senior Vice President of Discovery Research)Mark(Co-founder & Senior Vice President of Medicinal Chemistry)Mike(President & CEO)Charlotte(Chief Medical Officer)Elena(Chief Financial Officer)Caroline(Chief Business Officer)

Co-investorsOrbiMedRA Capital

Vima Therapeutics is a biotech company developing drug treatments for movement disorders such as dystonia and related neurological diseases.

BiotechHealthtechMedical Devices

Bernard Ravina(Founder and Chief Executive Officer)Judy Dunn(President of Research & Development)Jessica Fees(Chief Financial Officer)Ariel D. Jasie(Chief Business Officer and General Counsel)Tushar Misra(Chief Technical Officer)

Co-investorsFrazier Life SciencesAccess IndustriesAccess BiotechnologyCanaan Partners

TRIANA Biomedicines is a venture-backed biopharmaceutical company developing small-molecule "molecular glue" therapeutics that induce protein:protein interactions to degrade or alter disease-causing target proteins, with an initial focus on targeted protein degradation for cancer.

BiotechDeep TechHealthtechLexington, US

Patrick Trojer(President & CEO, Co-founder)

Co-investorsAscenta CapitalBessemer Venture PartnersLightspeed Venture PartnersPfizer VenturesRA CapitalPfizer Venture Investments

Developing drugs for rare cardiopulmonary disease.

Boston, US

Board seatDavid Grayzel· per SEC Form D · $75.8M raise · filed Aug 2020

Co-investorsSofinnova Ventures

Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.

AI & Machine LearningBiotechDeep TechWaltham, US

Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)Rick Modi(Chief Executive Officer, Board Member)

Board seatDavid Grayzel· per SEC Form D

Co-investorsEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)TCG Crossover+1 more

South San Francisco, US

Board seatKevin Bitterman· per SEC Form D · $45.5M raise · filed Dec 2018

Co-investorsvenBio Partners

BiotechSkillman, US

Simon Tomlinson(Executive Officer, Director)

BoardThomas Beck(Director)Benjamin Auspitz(Director)

Board seatDavid Grayzel· per SEC Form D · $22.5M raise · filed Jan 2018

HealthtechWaltham, US

Tillman Gerngross(Executive Officer, Director)

BoardAmy Schulman(Director)in

Board seatJean-François Formela· per SEC Form D · $10M raise · filed Dec 2022

Co-investorsPolaris Partners

BiotechSt. Louis, US

George H. Capps, II(Executive Officer)Robert Karr(Executive Officer, Director)David W. Griggs(Director)Thomas P. Cirrito(Director)

BoardCharles Bolten(Director)

Board seatPeter BarrettRajesh Devraj· per SEC Form D · $26M raise · filed Aug 2017

BiotechCambridge, US

Praveen Tipirneni(Executive Officer, Director)

BoardMichelle Doig(Director)inAaron Royston(Director)Xiaodi Su(Director)

Board seatMichael Gladstone· per SEC Form D

Co-investorsBain Capital Life SciencesJanus Henderson InvestorsLAVOmega FundsvenBio Global StrategicvenBio Partners+1 more

Boston, US

Board seatKevin Bitterman· per SEC Form D · $135M raise · filed Sep 2023

Co-investorsNewpath Partners

Day One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors.

BiotechHealthtechSouth San Francisco, US

Jeremy Bender(Executive Officer, Director)

BoardDerek DiRocco(Director)inJulie Papanek Grant(Director)inJohn Josey(Director)Daniel Becker(Director)

Board seatMichael Gladstone· per SEC Form D

Co-investorsAccess BiotechnologyCanaan PartnersRA CapitalThe Column Group

HealthtechPortland, US

Benjamin Shaw(Executive Officer, Director)David Shaw(Director)

BoardYumin Choi(Director)Philip Ferneau(Director)Edward McNamara(Director)

Board seatKevin Bitterman· per SEC Form D · $52.3M raise · filed Jul 2015

BiotechSt. Louis, US

Robert W. Karr(Executive Officer, Director)Bobby W. Sandage, Jr.(Executive Officer, Director)John Talley(Director)Robert J. Calcaterra(Director)

BoardCharles Bolten(Director)Rick Ryan(Director)

Board seatRajesh Devraj· per SEC Form D · $2.7M raise · filed Dec 2016

Co-investorsiSelect FundCultivation CapitalMissouri Technology Corporation

GRObio (GRO Biosciences) develops protein therapeutics using non-standard amino acids (NSAAs) via its GRO platform, aiming to improve protein potency, stability, and function.

BiotechDeep TechHealthtechCambridge, US

Daniel J Mandell(Executive Officer, Director)Tracey Lodie(Executive Officer)Christopher Gregg(Director)

BoardMing Fang(Director)Bruce Beutel(Director)Dan Becker(Director)

Board seatKevin Bitterman· per SEC Form D · $60.4M raise · filed Jul 2024

Co-investorsLeaps by BayerREDMILEDigitalis VenturesDreamers VCRising TideInnovation Endeavors+1 more

BiotechBoston, US

Gary Glick(Executive Officer, Director)Shelley Chu(Director)John Leonard(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

BiotechBoston, US

John Leonard(Director)Gary Glick(Executive Officer, Director)Shelley Chu(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

BiotechBoston, US

Gary Glick(Executive Officer, Director)John Leonard(Director)Shelley Chu(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Dec 2019

BiotechBoston, US

Gary D Glick(Executive Officer, Director)Vincent Miles(Director)

BoardJean-Francois Formela(Director)in

Board seatJean-François Formela· per SEC Form D · filed Aug 2018

BiotechBoston, US

Jotin Marango(Executive Officer)Mark Manfredi(Executive Officer, Director)Jeffrey Ecsedy(Executive Officer)Sergio Santillana(Executive Officer)Michelle Zhang(Executive Officer)

BoardOtello Stampacchia(Director)in

Board seatJean-François Formela· per SEC Form D · $75M raise · filed Jul 2025

Co-investorsBiotechnology Value FundForesite CapitalOmega FundsOrbiMedRTW Investments L.P.

BiotechWaltham, US

Timothy Springer(Director)Praveen Tiprirneni(Executive Officer, Director)Robert Farrell(Executive Officer)

BoardBarbara Dalton(Director)Ramy Farid(Director)

Board seatKevin Bitterman· per SEC Form D · $51.5M raise · filed Jul 2016

Co-investorsOmega FundsPolaris Partners

BiotechCambridge, US

Rick Lundberg(Executive Officer)George P. Vlasuk(Executive Officer, Director)George Vlasuk(Executive Officer, Director)

BoardJean-Francois Formela(Director)inAlan Crane(Director)Marian Nakada(Director)

Board seatKevin BittermanJean-François Formela· per SEC Form D

Co-investorsage1Brace PharmaSanofi VenturesPolaris PartnersSR One Capital Management

BiotechCambridge, US

Robert Prentiss(Executive Officer)Ronald C. Renaud, Jr.(Executive Officer, Director)Thomas McCauley(Executive Officer)

BoardBrian Gallagher(Director)Jean- Francois Formela(Director)inJoshua Resnick(Director)

Board seatJean-François Formela· per SEC Form D · $47.5M raise · filed May 2019

Co-investorsPfizer Venture Investments

Renasant Bio is a biopharmaceutical company developing oral small molecule corrector and potentiator therapies to restore the function of polycystin 1 and 2 proteins in autosomal dominant polycystic kidney disease (ADPKD).

BiotechHealthtechBerkeley, US

Jeremy Reiter(Scientific Co-Founder)Markus Delling(Scientific Co-Founder)Thomas Gustafson(Executive Officer)Emily Conley(Executive Officer, Director)

BoardEvan Caplan(Director)inCharlotte McKee(Director)

Board seatKevin Bitterman· per SEC Form D

Co-investors5AM VenturesOrbiMedQiming Venture Partners USA

BiotechBoston, US

Adam Friedman(Executive Officer, Director)Gary Glick(Executive Officer, Director)Andrew Fedder(Executive Officer)Darrin Stuart(Executive Officer)Erica Jackson(Executive Officer)Amanda Valentino(Executive Officer)

Board seatJean-François Formela· per SEC Form D

Co-investorsAvoro Capital AdvisorsEcoR1 CapitalFrazier Life SciencesNextech InvestVida VenturesLightspeed Venture Partners+2 more

Lexington, US

Board seatDavid Grayzel· per SEC Form D · $120.1M raise · filed Dec 2025

Co-investorsOpenSky VenturesThird Rock Ventures

Co-investorsLongwood Fund

Accent Therapeutics is a biotechnology company focused on discovering and developing small molecule drugs to improve health outcomes for cancer patients.

BiotechHealthtechLongevity

Co-investorsDroia VenturesEcoR1 CapitalGV (Google Ventures)The Column GroupJJDCJohnson & Johnson Innovation – JJDC+1 more

Akero develops engineered protein therapies for metabolic diseases, particularly MASH (metabolic dysfunction-associated steatohepatitis) and other conditions with high unmet medical need.

BiotechHealthtechMedical Devices

Co-investorsForesite CapitalFrazier Life SciencesScion Life SciencesThe Innovation SpacevenBio PartnersVersant Ventures

Alnylam is a biopharmaceutical company that supports investigator-initiated studies in therapeutic areas including transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria for medical researchers and healthcare professionals.

BiotechDigital HealthMedical Devices

John Maraganore(Founder)inDr. Yvonne Greenstreetin

Co-investorsARCH Venture PartnersBlackstone Life SciencesCardinal Partners

Arkuda is an independent information platform that provides analysis and reviews of online gaming platforms operating in Azerbaijan, focusing on legal compliance, security protocols, and user protection for gaming platforms like Mostbet.

ConsumerGamingBaku, AZ

Co-investorsMission BiocapitalPfizer Venture InvestmentsPfizer Ventures

Co-investorsAlta PartnersARCH Venture PartnersDC Investment PartnersLongwood FundNextech InvestPathway to Cures

Waltham, US

Patrick Morley(Executive Officer, Director)Eric Pyenson(Executive Officer)Gordon Pothier(Executive Officer)Richard Clarke(Director)

BoardRonald Nordin(Director)Jeff Fagnan(Director)

Co-investors.406 VenturesAccompliceEvolution Equity PartnersFounders Circle CapitalIntel CapitalKleiner Perkins+4 more

Verizon is a telecommunications company that provides wireless services and connectivity solutions to consumers and businesses.

Cloud ComputingEnterprise SoftwareNew York, US

Co-investorsMatrixNorth Atlantic CapitalNorwest Venture Partners

Advertising technology platform providing audience-based sales for television advertising.

Somerville, US

Joshua Summers(Executive Officer, Director, Promoter)Doug Hurd(Executive Officer, Director, Promoter)

BoardRyan Moore(Director)Lars Albright(Director)

Co-investorsBoston Seed CapitalTransmedia CapitalTribeca Venture PartnersData Point CapitalFreestyle CapitalWestern Technology Investment

Diagonal Therapeutics develops multi-specific clustering antibody therapeutics that bind multiple cell-surface receptors to activate or inhibit dysregulated signaling pathways underlying chronic diseases.

AI & Machine LearningBiotechHealthtechWatertown, US

Co-investorsEcoR1 CapitalFrazier Life SciencesSanofi Ventures

DisplayLink develops USB graphics system-on-chip technology that enables multiple display expansion across Windows, macOS, ChromeOS, Ubuntu, and Android devices regardless of underlying hardware architecture.

Enterprise SoftwareHardwareSemiconductors

Co-investorsBalderton CapitalDag Ventures

CybersecurityCambridge, US

Co-investorsBantam GroupTechstars

Earnest develops microbial seed coatings and agricultural biology products derived from prairie ecosystems to improve soil health and crop performance for farmers.

AgTechBiotechRantoul, US

Eddy Mejia(Co-founder)inDr. Gabe Price(Co-founder)

Co-investorsAg Ventures AllianceAgLaunch AcceleratorBoot64 VenturesAdams Street PartnersAndreessen HorowitzBattery Ventures+4 more

Egalet develops medicines for people living with moderate to severe pain, including approved and licensed pain products.

BiotechHealthtechMedical DevicesWayne, US

BARBARA A. CARLIN(SENIOR VICE PRESIDENT AND CHIEF ACCOUNTING OFFICER)ROBERT S. RADIE(CHIEF EXECUTIVE OFFICER)MARK STROBECK(EXECUTIVE VICE PRESIDENT AND CHIEF OPERATING OFFICER)MEGAN TIMMINS(SENIOR VICE PRESIDENT AND GENERAL COUNSEL)PATRICK M. SHEA(SENIOR VICE PRESIDENT AND CHIEF COMMERCIAL OFFICER)Jeffrey M. Dayno(Chief Medical Officer)

Co-investorsSunstone Capital

Co-investorsMC Healthcare Ventures

Boston, US

Co-investorsTechstarsMilitello Capital

BiotechCambridge, US

James McLaughlin(Executive Officer, Director)

BoardJean George(Director)Jason Rhodes(Director)Carl Gordon(Director)in

Co-investorsLightstone VenturesOrbiMed

BiotechCambridge, US

Geoff McDonoughy(Executive Officer, Director)Glenn Goddard(Executive Officer)Mark Angelino(Executive Officer)

BoardJason Rhodes(Director)inCatherine Stehman-Breen(Director)Anthony Quinn(Director)

Co-investorsForesite CapitalF-Prime CapitalInvus

Advanced ManufacturingDeep TechFintechHardwareSaaSCambridge, US

Hardi Meybaum(Executive Officer, Director)inIndrek Narusk(Executive Officer)

BoardDavid Skok(Director)

Co-investorsAsimov VenturesHeuristic Capital PartnersMatrixTechstarsTera VenturesNextView Ventures

Cambridge, US

Brendan Lattrell(Executive Officer, Director)

BoardDavid Balter(Director)

Co-investorsBantam GroupTechstarsKae CapitalPeak XV Partners

Grapevine operates a platform for Giving Circles that enables groups to pool donations, manage members, and direct funds to nonprofits.

Impact & Social GoodSaaSSocial

Emily RasmussenJessan Hutchinson-Quillian

Co-investorsDiagram CapitalKae CapitalNotation CapitalOverton Venture CapitalPJCUlu Ventures+1 more

Grapevine is a medical supply procurement service that negotiates prices, expands vendor networks, and reroutes orders to help clinics avoid overpaying and stay in stock.

B2B MarketplacesHealthtechLogistics & Supply Chain

Co-investorsThe MBA FundKae CapitalPeak XV Partners

BiotechHealthtech

Co-investorsAvoro Capital AdvisorsNew Enterprise Associates (NEA)

HotSpot Therapeutics is a drug discovery company developing small-molecule allosteric medicines by targeting "natural hotspots" — regulatory on/off switches on proteins.

AI & Machine LearningBiotechHealthtech

Co-investorsB Capital GroupB4 CapitalMRL Ventures FundSofinnova PartnersSolasta VenturesSR One Capital Management

ImageneBio is a clinical-stage biotechnology company developing therapeutics for patients with immunological, autoimmune, and inflammatory diseases.

BiotechHealthtechSan Diego, US

Co-investorsOrbiMed

K36 Therapeutics develops small-molecule inhibitors targeting the histone methyltransferase NSD2 for hematologic and solid tumor cancers.

BiotechHealthtech

Co-investorsF-Prime CapitalNextech Invest

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of product candidates for people living with obesity.

BiotechHealthtech

Co-investorsBain Capital Life SciencesCatalio Capital Management, LP

Cambridge, US

Sravish Sridhar(Executive Officer, Director)Jon Karlen(Director)

BoardFrank Castellucci(Director)Braden Bohrmann(Director)William Burnham(Director)Brady Bohrmann(Director)

Co-investorsAvalon Ventures Management, LlcBantam GroupNTT DOCOMO VenturesTechstarsVerizon Ventures

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsAccess BiotechnologyNextech InvestForbionRA Capital

Matchpoint Therapeutics is a drug discovery company developing precision small molecule covalent medicines to treat immune and inflammatory diseases.

AI & Machine LearningBiotechDeep Tech

Andre TurenneJared Cumming(PhD)Christopher HrenThomas Durand-Reville(PhD)Wei Li(MD)Paola Castaldi(PhD)

Co-investorsSanofi VenturesDigitalis Ventures

BiotechHealthtech

Jean-Paul Kress, M.D.in

Advanced ManufacturingMobility & TransportationAnn Arbor, US

Lihang Nong(Founder)in

Co-investorsY CombinatorGV (Google Ventures)

Nimbus provides automated cost optimization for Datadog customers, reducing their observability expenses without requiring manual intervention from engineering teams.

AI & Machine LearningData & InfrastructureEnterprise SoftwareSeattle, US

Kevin Lin(Founder)in

Co-investorsY CombinatorGV (Google Ventures)

HireNimbus is a mobile platform that connects homeowners with vetted local home service professionals for booking, payment, and job tracking.

AI & Machine LearningFintechImpact & Social GoodMarketplacesPropTechSaaSAlexandria, US

Satadru Sengupta(Founder)in

Co-investorsSamvid VenturesTechstarsGV (Google Ventures)

Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.

BiotechHealthtech

Peter Barrett(Co-founder & Board Member)Tom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)Parameswaran Hari(Chief Medical Officer)Julie Feder(Chief Financial Officer)Dana Alexander(Chief Technical Officer)

Co-investorsTCG CrossoverVertex Ventures HC

Nashville, US

Steven Berneman(Executive Officer, Director)Hunter Hillenmeyer(Executive Officer, Director)

BoardStuart Larkins(Director)inEric Satz(Director)

Co-investorsChicago VenturesMountain Group Capital

Digital banking and financial services for small businesses

Co-investorsAccompliceAcorn Pacific VenturesBling CapitalFirebolt Ventures Management Company, LlcFlybridge Capital PartnersKhosla Ventures+2 more

Recorded Future provides cyberthreat intelligence and AI-powered cyber defense capabilities to help organizations identify and neutralize critical threats.

AI & Machine LearningCybersecurityData & InfrastructureEnterprise SoftwareSomerville, US

Christopher Ahlberg(Executive Officer, Director)Staffan Truve(Director)

BoardLiautaud Bernard(Director)Rich Miner(Director)Jeff Fagnan(Director)Kevin Brown(Director)in

Co-investorsAccompliceBalderton CapitalBaukunstGula Tech AdventuresInsight PartnersMassMutual Ventures+1 more

HealthtechCambridge, US

Adam Rosenberg(Executive Officer, Director)

BoardBruce Booth(Director)Kees Been(Director)Samantha Singer(Director)

Co-investorsGV (Google Ventures)Hatteras Venture PartnersThird Point VenturesJJDCRemeditex Ventures

New York, US

Edward Kim(Executive Officer, Director)Kent Krekorian(Executive Officer)Hal Muchnick(Executive Officer, Director)Mark Peter Davis(Director)

BoardBo Peabody(Director)Benjamin Sun(Director)

Co-investorsMI VenturesSocial StartsMK CapitalSpring Mountain Capital

Co-investorsBain Capital Life Sciences

Merck is a pharmaceutical company focused on developing medicines and vaccines for patients globally, guided by a science-led innovation strategy.

BiotechHealthtechMedical DevicesRahway, US

Co-investorsAisling CapitalHM Venture PartnersSanderling VenturesSPRINGROCK VENTURESThe Column Group

Triveni Bio develops genetics-informed antibody therapeutics aimed at treating complex immunology and inflammation (I&I) diseases.

BiotechDigital HealthHealthtech

Vishal Patelin

Co-investorsBorealis VenturesBorealis VenturesMagnetic VenturesOrbiMedAscenta CapitalFidelity Investments+3 more

FintechBoston, US

Co-investorsBantam GroupTechstarsBoston Seed Capital

An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.

AI & Machine LearningBiotechMedical DevicesCambridge, US

Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)

Co-investorsLightstone VenturesVida VenturesHatteras Venture PartnersLongwood Fund

Nimbus Therapeutics designs and develops small molecule medicines using computational drug design and translational medicine.

BiotechDeep Tech

Co-investorsLightstone VenturesPfizer Venture Investments